Spectral Medical Future Growth

Future criteria checks 2/6

Spectral Medical is forecast to grow revenue at 24.6% per annum. EPS is expected to grow by 46.2% per annum.

Key information

n/a

Earnings growth rate

46.2%

EPS growth rate

Biotechs earnings growth	36.7%
Revenue growth rate	24.6%
Future return on equity	n/a
Analyst coverage	Low
Last updated	02 Apr 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

TSX:EDT - Analysts future estimates and past financials data (CAD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	3	N/A	N/A	N/A	1
12/31/2024	1	N/A	N/A	N/A	1
12/31/2023	2	-16	-11	-11	N/A
9/30/2023	2	-10	-11	-11	N/A
6/30/2023	2	-9	-10	-10	N/A
3/31/2023	2	-7	-11	-11	N/A
12/31/2022	2	-8	-10	-10	N/A
9/30/2022	2	-7	-10	-10	N/A
6/30/2022	1	-7	-10	-10	N/A
3/31/2022	2	-7	-10	-9	N/A
12/31/2021	2	-7	-9	-9	N/A
9/30/2021	2	-8	-9	-8	N/A
6/30/2021	2	-8	-9	-8	N/A
3/31/2021	2	-7	-8	-7	N/A
12/31/2020	2	-9	-1	0	N/A
9/30/2020	2	-8	-1	0	N/A
6/30/2020	2	-8	1	1	N/A
3/31/2020	3	-7	2	2	N/A
12/31/2019	3	-5	-3	-3	N/A
9/30/2019	4	-3	-2	-2	N/A
6/30/2019	4	-2	-2	-1	N/A
3/31/2019	3	-3	-2	-2	N/A
12/31/2018	4	-2	-2	-2	N/A
9/30/2018	3	-4	-3	-3	N/A
6/30/2018	3	-4	-3	-3	N/A
3/31/2018	4	-4	-3	-3	N/A
12/31/2017	4	-4	-4	-4	N/A
9/30/2017	4	-4	N/A	-5	N/A
6/30/2017	4	-6	N/A	-7	N/A
3/31/2017	3	-8	N/A	-9	N/A
12/31/2016	4	-10	N/A	-11	N/A
9/30/2016	3	-11	N/A	-11	N/A
6/30/2016	3	-11	N/A	-10	N/A
3/31/2016	3	-10	N/A	-9	N/A
12/31/2015	3	-10	N/A	-9	N/A
9/30/2015	3	-10	N/A	-9	N/A
6/30/2015	3	-9	N/A	-9	N/A
3/31/2015	3	-9	N/A	-9	N/A
12/31/2014	3	-9	N/A	-10	N/A
9/30/2014	3	-11	N/A	-11	N/A
6/30/2014	3	-12	N/A	-10	N/A
3/31/2014	3	-12	N/A	-10	N/A
12/31/2013	3	-11	N/A	-9	N/A
9/30/2013	3	-10	N/A	-8	N/A
6/30/2013	3	-9	N/A	-9	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if EDT's forecast earnings growth is above the savings rate (2%).

Earnings vs Market: Insufficient data to determine if EDT's earnings are forecast to grow faster than the Canadian market

High Growth Earnings: Insufficient data to determine if EDT's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: EDT's revenue (24.6% per year) is forecast to grow faster than the Canadian market (6.6% per year).

High Growth Revenue: EDT's revenue (24.6% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if EDT's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Spectral Medical Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Price target increased by 13% to CA$1.80

Consensus revenue estimates increase by 186%

Consensus revenue estimates decrease by 61%, EPS upgraded

No longer forecast to breakeven

Consensus forecasts updated

Consensus forecasts updated

Recent updates

Spectral Medical Provides Tigris Trial Update

Less than half of directors are independent

Price target increased by 13% to CA$1.80

Spectral Medical Inc. Announces Board Changes

Full year 2023 earnings: EPS and revenues miss analyst expectations

Spectral Medical Inc., Annual General Meeting, Jun 07, 2024

New minor risk - Market cap size

Spectral Medical Inc. Provides Update on the Company's Tigris Trial

Spectral Medical Announces Major Milestone by Reaching Its Interim Enrollment Target of 90 Patients

Spectral Medical Inc. Provides Early February Tigris Trial Update

Spectral Medical Provides January Tigris Trial Update

Spectral Medical Inc. l Enrolls Patient 82 in Its Phase 3 FDA Tigris Septic Shock Trial

Spectral Medical Inc. Provides November Tigris Trial Update

Spectral Medical Inc. Announces Executive Changes

Spectral Medical Inc. Announces Executive Changes

Spectral Medical Inc. Announces Publication of Tigris Trial Methods Paper

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Spectral Medical Provides Tigris Trial Update

New minor risk - Shareholder dilution

Spectral Medical Inc. announced that it has received CAD 6.217075 million in funding

Spectral Medical Inc. announced that it expects to receive CAD 5 million in funding from Paradigm Capital Inc.

Second quarter 2023 earnings released: CA$0.014 loss per share (vs CA$0.011 loss in 2Q 2022)

Spectral Medical Inc. Announces Tigris Clinical Trial Update

Spectral Medical Inc. Appoints David W. Feigal to Its Board of Directors

Spectral Medical Inc. Provides Update on Continued Favorable Tigris Clinical Trial Enrollment

Spectral Medical Inc. Provides Update on Favorable Tigris Clinical Trial Enrollment

Consensus revenue estimates increase by 186%

Consensus revenue estimates decrease by 61%, EPS upgraded

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Spectral Medical Inc. Announces Resignation of Jim Funk as Director

No longer forecast to breakeven

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Spectral Medical Inc. Provides Update on Tigris Clinical Trial

Consensus forecasts updated

Consensus forecasts updated

Price target decreased to CA$2.10

Forecast to breakeven in 2024

Spectral Medical Inc. announced that it has received CAD 6.8364 million in funding

Spectral Medical Inc. announced that it expects to receive CAD 8.5 million in funding

Spectral Medical Inc. announced that it expects to receive CAD 8.5 million in funding

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Spectral Medical Provides Update on Tigris Clinical Trial

US FDA Grants Spectral Medical Breakthrough Device Designation for Toraymyxin™ for the Treatment of Endotoxemic Septic Shock

Spectral Medical Inc. Elects James Funk as Director

Spectral Medical Inc. Appoints Sam Amory as Dialco, President

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Price target decreased to CA$2.10

Forecast breakeven date pushed back to 2024

Consensus revenue estimates fall by 44%

Spectral Medical Inc., Annual General Meeting, Jun 09, 2022

Spectral Medical Inc. Through Its Wholly-Owned Subsidiary Dialco Medical Inc. Provides Clinical Trial Update on Tigris, A Follow on Study Designed to Build on Knowledge Gained from the Earlier Euphrates Trial

We're Keeping An Eye On Spectral Medical's (TSE:EDT) Cash Burn Rate

Forecast to breakeven in 2023

Third quarter 2021 earnings released: CA$0.008 loss per share (vs CA$0.007 loss in 3Q 2020)

Price target decreased to CA$2.85

Independent Chairman of the Board recently bought CA$180k worth of stock

Independent Director Kevin Giese has left the company

Forecast breakeven moved forward to 2022

First quarter 2021 earnings released: CA$0.007 loss per share (vs CA$0.015 loss in 1Q 2020)

Consensus forecasts updated

Full year 2020 earnings released: CA$0.039 loss per share (vs CA$0.022 loss in FY 2019)

Spectral Medical Inc.'s (TSE:EDT) Path To Profitability

Spectral Medical Inc., Annual General Meeting, Jun 03, 2021

Independent Director exercised options to buy CA$104k worth of stock.

Spectral Medical Inc. Announces Chief Executive Officer Changes, Effective April 1, 2021

Spectral Medical Inc Crescendo Communications to Provide Investor Relations Services in the United States

Spectral Medical Announces That Its Wholly-Owned Subsidiary Dialco Medical Has Been Granted FDA IDE Authorization to Conduct Trial of Dimi for Home Hemodialysis Use

Spectral Medical (TSE:EDT) Is In A Good Position To Deliver On Growth Plans